Seizure control following treatment of brain arteriovenous malformations in pediatric patients

Xiangke Ma1,2,3,4, Xianzeng Tong1,2,3,4, Jun Wu1,2,3,4

  • 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.

Insights

Pediatric brain arteriovenous malformations (AVMs) larger in size, in the frontal lobe, or with prior hemorrhage increase seizure risk. Complete AVM obliteration via microsurgery offers the best seizure control.

Area of Science:

  • Neurology
  • Neurosurgery
  • Pediatric Neurology

Background:

  • Arteriovenous malformations (AVMs) are complex vascular lesions in the brain.
  • Seizure outcomes in pediatric patients with brain AVMs are not well-documented.
  • Understanding seizure presentation and control is crucial for managing pediatric AVMs.

Purpose of the Study:

  • To identify risk factors for seizure presentation in pediatric brain AVM patients.
  • To determine predictors of seizure control after AVM treatment.
  • To analyze seizure occurrence and outcomes in a pediatric cohort.

Main Methods:

  • Retrospective analysis of 198 pediatric brain AVM patients (2009-2014).
  • Data collected on seizure presentation, patient/AVM characteristics, treatments, and outcomes.
  • Logistic regression used to identify risk factors and predictors.

Main Results:

  • 31.8% of patients presented with seizures.
  • Larger AVM size, frontal location, and prior hemorrhage predicted seizure presentation.
  • 73.8% of patients with pre-treatment seizures achieved good seizure control; AVM obliteration was a key predictor.
  • 4.4% developed de novo seizures after treatment.

Conclusions:

  • Prior hemorrhage, larger AVM size, and frontal lobe location are associated with seizures in pediatric brain AVMs.
  • Complete AVM obliteration, particularly through microsurgical resection, is linked to the highest seizure control rates.
  • These findings aid in predicting and managing seizures in pediatric AVM patients.
Abstract

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K